ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO410

The Analysis of Long-Term Course of Tolvaptan Treatment and the Study Using Kidney and Liver Derived Cyclic AMP in Autosomal Dominant Polycystic Kidney Disease

Session Information

Category: Genetic Diseases of the Kidneys

  • 1101 Genetic Diseases of the Kidneys: Cystic


  • Nakatani, Yoshihisa, Kinki Daigaku Igakubu Daigakuin Igaku Kenkyuka, Osakasayama, Osaka, Japan
  • Nakano, Yukihito, Kinki Daigaku Igakubu Daigakuin Igaku Kenkyuka, Osakasayama, Osaka, Japan
  • Arima, Shuji, Kinki Daigaku Igakubu Daigakuin Igaku Kenkyuka, Osakasayama, Osaka, Japan

cAMP (Cyclic AMP) in the kidney and liver of ADPKD(Autosomal dominant polycystic kidney disease)persons cannot be measured directly. We will calculate the cAMP secreted from the kidney and liver and examine the increase of their volumes and renal prognosis.


Sixty ADPKD persons who have visited Kindai University hospital from January 2016 to January 2022. ADPKD was diagnosed, and twenty-five of them were introduced to TVP by hospitalization. After diagnosis, eGFR, plasma / urine cAMP and kidney volume were measured over time and examined. Renal and hepatic Plasma and urine cAMP was calculated.


Renal cAMP was correlated with kidney volume at eGFR 30 or higher, but hepatic cAMP did not correlate with liver volume. However, abnormally high liver cAMP was observed in patients who had no longer infected with giant hepatic cyst, which was correlated with the size of the cyst. Renal cAMP was not significantly correlated with ΔeGFR, but the higher the renal cAMP, the higher the rate of renal volume increase. Before and after oral administration of TVP, renal cAMP decreased significantly from 18.0 ± 8.0 to 10.4 ± 3.4, but hepatic cAMP showed almost no change. TKV changed to the rate of +9.27% (before administration), -3.96% (1 year later), -0.80% (2 years later), and + 4.24% (3 years later) by TVP administration. And the ΔeGFR is -6.7 ml / min (before administration) → 1 year later -3.6 ml / min (1 year later), -3.0 ml / min (2 years later) → -3.5 ml / min (3 years later).So, we could suppress enlargement on kidney volume and the decline in renal function. Although renal cAMP dramatically decreased in an abbreviated time in patients who began to take TVP, there were any cases in which renal cAMP increased again during treatment if the amount of TVP taken was not sufficient.


Renal cAMP can be a marker for the predict of ADPKD renal volume development and the increase of TVP dose. However, it was found that hepatic cAMP was not a marker for liver volume development and was not affected by TVP.